Table of Contents: CATIE News - 2002
Canadian AIDS Treatment Information Exchange
Edited by: Alan Boutilier and Sean Hosein

Table Of Contents

December
Sixth International Congress on Drug Therapy in HIV Infection: Glasgow Scotland - What's a conference about?; Who gets treatment and...side effects; Rub-on vaccine study planned; Is hepatitis C virus going to become a major STD?; Syphilis - the great masquerader; Tea tree oil looks promising against oral fungus; Capsule exposes guts, reduces need for poking; Directly-observed therapy in HIV positive heroin users; New drug holds promise of once-daily therapy
November
Company backs out of immune drug study
October
Hepatitis C and its effect on the response to HAART; Hepatitis News Briefs
September
Nevirapine and vivid dreams; Ecstasy can cause anemia in HAART users; Cancer drug for male breast enlargement?
August
From The XIV International AIDS Conference: Efavirenz makes its mark in AIDS; From The XIV International AIDS Conference: T-20 shows its potency; From The XIV International AIDS Conference: Efavirenz in PHAs with fungal infections of the brain; From The XIV International AIDS Conference: Efavirenz: Who is at high risk for brain side effects?; From The XIV International AIDS Conference: Efavirenz long-term side effects; The Buzz from Barcelona: Canadian impressions of The XIV International AIDS Conference; Canada says no to kava; Kava toxicity: Does the answer lie in preparation?
July
Warning: Beware of grapefruit and its juice; Lopinavir vs. nelfinavir — more issues to consider; Overview of The XIV International Conference on HIV/AIDS; From The XIV International AIDS Conference: American-Italian study produces unexpected results; From The XIV International AIDS Conference: Tenofovir looks good in initial therapy; From The XIV International AIDS Conference:Tenofovir and Videx EC — some caution required; From The XIV International AIDS Conference:Study finds fatigue linked to quality of sleep
May
Highlights from the 3rd International Workshop on Clinical Pharmacology of HIV Therapy; Fine-tuning saquinavir; Saquinavir with low-dose ritonavir twice daily; Invirase vs. Fortovase: unexpected results?; Saquinavir once daily; Company warns about tampered labels for Combivir in the U.S.
April
British study looks at cervical growths and HAART; Sex hormones and HAART;
March
9th Retrovirus Overview; Switching to abacavir to reduce fat wasting; Cause of serious illness among HAART-users not clear; Using abacavir to avoid lipid problems
February
Nevirapine levels may predict toxicity; Adverse drug reactions in Canada; Health Canada advises against kava; Birth defect in baby born to efavirenz-user; Complex cocktails require testing; Viagra and grapefruit juice -- not a good mix; Efavirenz helps get rid of Kaposi's sarcoma;
January
Recovery from cocaine addiction needs more than just acupuncture; St. John's wort can lower cholesterol drug levels
Copyright / Funding / How to reach CATIE
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980,2002. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.